BackHenan Lingrui Pharmaceutical , Ltd. Overview

Henan Lingrui Pharmaceutical , Ltd. Receivables

Track Henan Lingrui Pharmaceutical , Ltd.'s receivables ($890M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$891.85M
↑ 13.71% YoYΔ $107.51M vs prior year quarter

Peer trimmed avg / median

Loading

Henan Lingrui Pharmaceutical , Ltd. Receivables History

Loading

Henan Lingrui Pharmaceutical , Ltd. vs. peers: Receivables Comparison

Loading

Henan Lingrui Pharmaceutical , Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Henan Lingrui Pharmaceutical , Ltd. (600285.SS) FAQ

As of the most recent data (June 2026), 600285.SS shows a receivables of $890M. That compares with $780M in the prior-year period — up 13.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 600285.SS's receivables is now $890M (was $780M) — a 13.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Henan Lingrui Pharmaceutical , Ltd. is outperforming or lagging.

Tracking 600285.SS's receivables over time shows whether Henan Lingrui Pharmaceutical , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $890M That compares with $780M in the prior-year period — up 13.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Henan Lingrui Pharmaceutical , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $890M) with ownership activity and broader fundamentals.